Mielicki W P, Tenderenda M, Rutkowski P, Chojnowski K
Department of Biochemistry, Medical University of Lodz, Institute of Environmental Research and Bioanalysis, Poland.
Cancer Lett. 1999 Nov 1;146(1):61-6. doi: 10.1016/s0304-3835(99)00230-x.
The activity of cancer procoagulant (CP), prothrombin time (PT), activated partial thromboplastin time (APTT), the concentration of thrombin-antithrombin complexes (TAT) and the concentration of fibrinogen were analysed in blood of breast cancer patients scheduled for surgery. The serum level of CP activity was dependent on the stage of the disease. The CP activity was increased in 72% of patients with an early stage of cancer and in only 20% of patients with an advanced stage of the disease when compared to the baseline level for non-cancer controls. In all patients PT remained at normal levels (80-120%). There was no significant change in APTT (27-39 s) in early stage cancer patients. Only one patient with advanced cancer had APTT shortened to 23 s. Also one advanced stage patient had significantly elevated level of TAT (14.96 microg/l); in all other patients the concentration of TAT remained at normal levels (1-4.1 microg/l). Forty-four percent of early stage cancer patients and 22% of advanced cancer patients had an elevated level of fibrinogen (Fg) ( > 350 mg%). However, there was no correlation between the level of Fg and the CP activity (P > 0.05). The data suggest that: (1) serum CP activity increases at the early stage of breast cancer and decreases down to the normal level in the advanced stage of the disease; (2) there is no evidence of blood clotting activation in the early stage breast cancer patients; and (3) CP does not facilitate the activation of coagulation in the breast cancer patients or the level of such activation is below the sensitivity of assays used in the experiment.
对计划接受手术的乳腺癌患者血液中的癌促凝剂(CP)活性、凝血酶原时间(PT)、活化部分凝血活酶时间(APTT)、凝血酶 - 抗凝血酶复合物(TAT)浓度以及纤维蛋白原浓度进行了分析。血清CP活性取决于疾病分期。与非癌症对照的基线水平相比,72%的早期癌症患者CP活性升高,而晚期疾病患者中只有20%的患者CP活性升高。所有患者的PT均保持在正常水平(80 - 120%)。早期癌症患者的APTT(27 - 39秒)无显著变化。只有一名晚期癌症患者的APTT缩短至23秒。还有一名晚期患者的TAT水平显著升高(14.96微克/升);所有其他患者的TAT浓度保持在正常水平(1 - 4.1微克/升)。44%的早期癌症患者和22%的晚期癌症患者纤维蛋白原(Fg)水平升高(>350毫克%)。然而,Fg水平与CP活性之间无相关性(P>0.05)。数据表明:(1)乳腺癌早期血清CP活性升高,疾病晚期降至正常水平;(2)早期乳腺癌患者无血液凝固激活的证据;(3)CP在乳腺癌患者中不促进凝血激活,或这种激活水平低于实验中所用检测方法的灵敏度。